Concept of optimal surgical cytoreduction in advanced ovarian cancer: A brief critique and a call for action

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4168-4170

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MORBIDITY; NOTE; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT; ARTICLE; FEMALE; LYMPH NODE METASTASIS; METHODOLOGY; OVARY TUMOR; PATHOLOGY; TREATMENT OUTCOME;

CLINICAL TRIALS; FEMALE; HUMANS; LYMPHATIC METASTASIS; OVARIAN NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 34948863860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.8992     Document Type: Note

References (23)

1. Covens AL: A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78:269-274, 2000
2. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101-104, 1975
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
4. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
5. Girling JC, Soutter WP: Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: A topic for debate. Int J Gynecol Cancer 81-84, 1996
6. Hunter RW, Alexander ND, Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166:504-511, 1992
7. Hoskins WJ, Bundy BN, Thigpen JT, et al: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 47:159-166, 1992
8. van der Burg ME, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer: Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332:629-634, 1995
9. Redman CW, Warwick J, Luesley DM, et al: Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 101:142-146, 1994
10. Rose PG, Nerenstone S, Brady MF, et al: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489-2497, 2004
11. Eisenkop SM, Spirtos NM: What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82:489-497, 2001
12. Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 69:103-108, 1998
13. Eisenkop SM, Spirtos NM, Friedman RL, et al: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study. Gynecol Oncol 90:390-396, 2003
14. Aletti GD, Dowdy SC, Gostout BS, et al: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77-85, 2006
15. Chi DS, Eisenhauer EL, Lang J, et al: What is the optimal goal of primary cytoreductive surgery for bulky stage IMC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559-564, 2006
16. Chi DS, Franklin CC, Levine DA, et al: Improved optimal cytoreduction rates for stages NIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: A change in surgical approach. Gynecol Oncol 94:650-654, 2004
17. Harlan LC, Clegg LX, Trimble EL: Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21:3488-3494, 2003
18. Carney ME, Lancaster JM, Ford C, et al: A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 84:36-42, 2002
19. Junor EJ, Hole DJ, McNulty L, et al: Specialist gynaecologists and survival outcome in ovarian cancer: A Scottish national study of 1866 patients. Br J Obstet Gynaecol 106:1130-1136, 1999
20. Bach PB, Cramer LD, Schrag D, et al: The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 345:181-188, 2001
21. Begg CB, Riedel ER, Bach PB, et al: Variations in morbidity after radical prostatectomy. N Engl J Med 346:1138-1144, 2002
22. Birkmeyer JD, Stukel TA, Siewers AE, et al: Surgeon volume and operative mortality in the United States. N Engl J Med 349:2117-2127, 2003
23. Birkmeyer JD, Siewers AE, Finlayson EV, et al: Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128-1137, 2002